NASDAQ · EOLSHealthcarePharmaceuticals

Evolus financials

$7.99+0.38%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$297.2M$266.3M$202.1M$148.6M$99.7M$56.5M$34.9M$0.00
Gross profit$197.1M$182.3M$137.6M$89.8M$56.1M$38.2M$26.9M$0.00
Gross margin66.3%68.5%68.1%60.4%56.3%67.6%77.1%—
Operating income-$32.7M-$34.4M-$49.2M-$65.3M-$38.1M-$155.1M-$94.8M-$46.1M
Net income-$51.6M-$50.4M-$61.7M-$74.4M-$46.8M-$163.0M-$90.0M-$46.9M
Net margin−17.4%−18.9%−30.5%−50.1%−47.0%−288.3%−257.8%—
Diluted EPS$-0.80$-0.81$-1.08$-1.33$-0.94$-4.83$-3.19$-1.92
EBITDA-$23.7M-$29.1M-$44.1M-$55.9M-$57.3M-$61.0M-$89.8M-$35.6M
Operating cash flow-$42.3M-$18.0M-$34.0M-$84.9M-$33.4M-$57.9M-$93.4M-$25.7M
Free cash flow-$50.7M-$22.8M-$35.6M-$87.9M-$34.4M-$61.0M-$98.0M-$25.7M
Diluted shares64.5M62.0M56.9M56.1M49.8M33.7M28.2M24.4M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$53.8M$87.0M$62.8M$53.9M$146.3M$102.6M
Short-term investments$0.00$0.00$0.00$0.00—$5.0M
Total debt$179.6M$166.3M$156.6M$111.7M$110.6M$153.0M
Total assets$225.9M$232.6M$189.0M$178.0M$257.5M$209.1M
Total liabilities$249.0M$227.0M$209.7M$159.5M$175.6M$282.0M
Shareholders' equity-$23.1M$5.5M-$20.7M$18.5M$81.9M-$73.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology